Cardeas Pharma
Seattle
About Cardeas Pharma
Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $80.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2015)
- Website: cardeaspharma.com
- Phone: 206-336-5550
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/cardeas-pharma-3351537 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.